New Risk • Jul 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (4.5% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Large one-off items impacting financial results. Announcement • Jul 01
MicroPort Scientific Corporation Appoints Dr. Yingyao Chen as an Independent Non-executive Director MicroPort Scientific Corporation announced that at its AGM held on June 30, 2026, Dr. Yingyao Chen has been elected as an independent non-executive Director of the Company. His biographical details are set out below: Dr. Chen, born in 1968, is an expert in health technology assessment and hospital management. Dr. Chen currently serves as a Professor and Vice Dean of the School of Public Health, Fudan University, Director of the Key Laboratory of Health Technology Assessment of the National Health Commission, Director of the World Health Organization Collaborating Centre for Health Technology Assessment, Chairman of the Health Technology Assessment Professional Committee of the China Medicinal Biotech Association, Chairman of the Health Technology Assessment and Policy Research Professional Committee of the China Association for Medical Devices Industry, Vice Chairman of the Health Technology and Economic Evaluation Professional Committee of the China Health Economics Association, and Vice President of Shanghai Association for Maternal and Child Health and Improving Birth Outcome and Child Development. Dr. Chen has long been engaged in research in health technology assessment, hospital management and public health programme evaluation. He has led a number of research projects of the World Health Organization, the World Bank, the National Health Commission, the National Healthcare Security Administration, among others. Dr. Chen has served as chief editor of a number of national core textbooks, and has published extensively as first author or corresponding author in domestic and international core journals, including the British Medical Journal. From 1991 to 1999, Dr. Chen served as an Assistant Professor and Lecturer at the School of Public Health of Shanghai Medical University. From 1999 to 2001, he was a visiting scholar at the UCLA Fielding School of Public Health. Dr. Chen returned to the School of Public Health of Fudan University in 2001. Dr. Chen obtained his Bachelor's degree in Medicine and Master's degree in Medicine from Shanghai Medical University in 1991 and 1997, respectively, and obtained his Doctoral degree in Management from Fudan University in 2006. Announcement • Jun 09
MicroPort Scientific Corporation, Annual General Meeting, Jun 30, 2026 MicroPort Scientific Corporation, Annual General Meeting, Jun 30, 2026, at 10:00 China Standard Time. Location: 1601 zhangdong road, zhangjiang hi-tech park, shanghai 201203, China Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Chunyang Shao was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Mar 19
MicroPort Scientific Corporation to Report Fiscal Year 2025 Results on Mar 31, 2026 MicroPort Scientific Corporation announced that they will report fiscal year 2025 results on Mar 31, 2026 Announcement • Jan 23
MicroPort Scientific Corporation Provides Consolidated Earnings Guidance for the Year Ended 31 December 2025 MicroPort Scientific Corporation provided consolidated earnings guidance for the year ended 31 December 2025. The Group is expected to achieve a turnaround to profitability for the year ended 31 December 2025 (the Period), recording a net profit of not less than USD 20 million (for the year ended 31 December 2024: audited net loss of approximately USD 268 million). Board Change • Dec 30
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Chunyang Shao was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Sep 22
Shanghai MedTech Medical Equipment Partnership Enterprise completed the acquisition of 7.3% stake in MicroPort Scientific Corporation (SEHK:853) from Otsuka Medical Devices Co., Ltd. Shanghai MedTech Medical Equipment Partnership Enterprise reached an Share Transfer Agreement to acquire 7.3% stake in MicroPort Scientific Corporation (SEHK:853) from Otsuka Medical Devices Co., Ltd. on July 25, 2025. In related transaction, WeTron Capital Limited reached an Share Transfer Agreement to acquire an additional 7.3% stake in MicroPort Scientific from Otsuka Medical Devices and Goal Carol Limited, Jonathan W Chen and Jumbo Glorious Limited reached an Share Transfer Agreement to acquire 1.1% stake in MicroPort Scientific from Otsuka Medical Devices. Following the transaction, Otsuka Medical Devices will hold a 4.99% stake in MicroPort Scientific.
The closing shall take place upon obtaining approval from relevant governmental authorities. BofA Securities, Inc. acted as financial advisor to Otsuka Medical Devices Co., Ltd.
Shanghai MedTech Medical Equipment Partnership Enterprise completed the acquisition of 7.3% stake in MicroPort Scientific Corporation (SEHK:853) from Otsuka Medical Devices Co., Ltd on September 22, 2025. Announcement • Aug 19
MicroPort Scientific Corporation to Report First Half, 2025 Results on Aug 29, 2025 MicroPort Scientific Corporation announced that they will report first half, 2025 results on Aug 29, 2025 Announcement • Jul 18
Microport Scientific Corporation Provides Earnings Guidance for the Six Month Ended 30 June 2025 MicroPort Scientific Corporation provided earnings guidance for the six month ended 30 June 2025. The Group is estimated the revenue of the Group slightly decreased by no more than 4% year-on-year (excluding the effect of exchange rate). Among them, except the surgical robot business, all of the other major business segments recorded revenue decline or growth slowdown to varying extents. Announcement • Apr 30
Shanghai Fund Is Said to Weigh Buying Otsuka’s Stake in MicroPort A fund backed by Shanghai Industrial Investment (Holding) Co., Ltd. is in talks to buy Otsuka Holdings Co., Ltd. (TSE:4578)’s stake in Chinese medical device maker MicroPort Scientific Corporation (SEHK:853), according to people familiar with the situation. Otsuka has been considering options for its holding in Hong Kong-listed MicroPort, including selling it, Bloomberg News reported in October. The Japanese drugmaker’s stake was about 20.9% as of the end of June. Announcement • Apr 29
MicroPort Scientific Corporation, Annual General Meeting, May 30, 2025 MicroPort Scientific Corporation, Annual General Meeting, May 30, 2025, at 10:00 China Standard Time. Location: 1601 zhangdong road, zhangjiang hi-tech park, shanghai 201203, China Announcement • Mar 18
MicroPort Scientific Corporation to Report Fiscal Year 2024 Results on Mar 28, 2025 MicroPort Scientific Corporation announced that they will report fiscal year 2024 results on Mar 28, 2025 New Risk • Oct 01
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$53m net loss in 2 years). Reported Earnings • Sep 29
First half 2024 earnings released: US$0.053 loss per share (vs US$0.089 loss in 1H 2023) First half 2024 results: US$0.053 loss per share (improved from US$0.089 loss in 1H 2023). Revenue: US$558.7m (up 16% from 1H 2023). Net loss: US$96.8m (loss narrowed 41% from 1H 2023). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 47% per year, which means it is performing significantly worse than earnings. Announcement • Aug 20
MicroPort Scientific Corporation to Report First Half, 2024 Results on Aug 30, 2024 MicroPort Scientific Corporation announced that they will report first half, 2024 results on Aug 30, 2024 Announcement • Jul 30
MicroPort Scientific Corporation Announces Firesorb Bioresorbable Coronary Scaffold System Obtained Approval for Marketing from the NMPA The board of directors of MicroPort Scientific Corporation announced that on 30 July 2024, the new generation Firesorb Bioresorbable Scaffold System (‘Firesorb Stent’), self- developed by the Group, obtained the approval for marketing from the National Medical Products Administration of China (the ‘NMPA’), which will further improve the Group's integrated, precise and intelligent holistic solutions for the diagnosis and treatment of coronary artery-related diseases, in order to serve the comprehensive needs of patients worldwide. About Firesorb Stent: First Target Eluting Bioresorbable Scaffold System with Reduced Strut Thickness to Same Level as Metal Stents While Maintaining Equal Support The Group adopted thin strut design which made Firesorb Stent the first target eluting bioresorbable scaffold system with reduced strut thickness to same level as metal stents while maintaining equal support. The Rate of Thrombosis of All Patients in the FUTURE-I, II and III Three Trials was only 0.32% at 2-year Follow up, with a Four-year Thrombotic Event of 0% in the RCT Study Data from large preclinical studies have shown that Firesorb Stent is non-inferior to permanent drug-eluting stents in terms of major clinical parameters from publicly available clinical data. Firesorb Stent has a target lesion failure (TLF) rate of only 4.3% at 4-year follow-up of RCT study. The rate of thrombosis of all patients in the FUTURE-I, II, and III Trials was only 0.32% at 2-year follow up, with four-year thrombotic event of 0% in the RCT study. The imaging results supports that Firesorb Stent is not inferior to other marketed permanent stents in terms of endothelial coverage rate and speed, and the numerical results of the clinical trial are superior compared to other biodegradable stents. Target Eluting Technology to Reduce Effective Drug Load while Achieving Same Efficacy Adopting the unique ‘target eluting’ technology of MicroPort, Firesorb Stent achieves precisely targeted drug application, coating only one side of the stent facing the vessel wall and reducing the effective drug load to one-third of the universal drug load while achieving the same efficacy. Wider Lesion Size Coverage As a bioresorbable stent with wider lesion size coverage and applicable to the treatment of small- vessel lesions up to 2.5 millimeters in diameter, Firesorb Stent solves the problem of accessibility of bioresorbable stent in small-vessel lesion areas. Meanwhile, the guidewire for rotational atherectomy, which is used in conjunction with the Group's first self-developed rotational atherectomy catheter system and coronary rotational atherectomy system, has recently obtained marketing approval from the NMPA, and the coronary rotational atherectomy system has entered the NMPA special review approval process for innovative medical devices (the ‘Green Path’). Impact on the Company. Improve the Diagnosis Holistic Medical Solutions for the Treatment of Cardiovascular Diseases to Bring New Growth Momentum The marketing approval of Firesorb Stent and guidewire for rotational atherectomy by the NMPA will further improve the Group's integrated, precise and intelligent holistic solutions for the diagnosis and treatment of coronary artery-related diseases, in order to serve the comprehensive needs of patients worldwide. Leveraging on the commercialisation capability of the Group's existing cardiovascular interventional product channels and overseas platforms, it is believed that new growth momentum will be brought to the Group. Strengthen the Leading Position in the Global Coronary Stent Field The incidence of coronary heart disease is trending younger. Bioresorbable stents, which can support diseased blood vessels in the short term and degrade completely in the body in the long term, are at the scientific and technological hub amid the global competition. The approval of Firesorb Stent will further strengthen the Group's leading position in the global coronary stent field. Application of Technologies Derived from Platform The technologies derived from Firesorb Stent platform are expected to be applied in other areas such as cerebral infarction, peripheral vascular stenosis, and bone trauma in the future, allowing more patients to access internationally leading treatment solutions. Announcement • May 23
Microport Scientific Corporation Announces Retirement of Non-Executive Directors The Board of MicroPort Scientific Corporation announced that Dr. Qiyi Luo and Mr. Bo Peng, being non-executive directors of the Company, who did not offer themselves for re-election at the AGM in order to allow themselves to devote more time to their personal endeavours, have retired as non-executive directors of the Company at the conclusion of the AGM. Meanwhile, Dr. Qiyi Luo and Mr. Bo Peng have resigned as members of the strategy committee (the "Strategy Committee") of the Board at the conclusion of the AGM. Dr. Qiyi Luo and Mr. Bo Peng have confirmed that they have no disagreement with the Board and there is no matter in relation to their retirement that needs to be brought to the attention of the Shareholders of the Company. Announcement • Apr 06
MicroPort Scientific Corporation, Annual General Meeting, May 22, 2024 MicroPort Scientific Corporation, Annual General Meeting, May 22, 2024. Reported Earnings • Mar 29
Full year 2023 earnings released: US$0.26 loss per share (vs US$0.24 loss in FY 2022) Full year 2023 results: US$0.26 loss per share (further deteriorated from US$0.24 loss in FY 2022). Revenue: US$950.7m (up 13% from FY 2022). Net loss: US$477.6m (loss widened 9.4% from FY 2022). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings. Announcement • Mar 19
MicroPort Scientific Corporation to Report Fiscal Year 2023 Results on Mar 28, 2024 MicroPort Scientific Corporation announced that they will report fiscal year 2023 results on Mar 28, 2024 New Risk • Dec 09
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 9.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.4% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$188m net loss in 2 years). Announcement • Nov 11
MicroPort Scientific Corporation Announces Appointment of Peng Bo as Non-Executive Director and Member of the Strategic Committee MicroPort Scientific Corporation announces that Mr. Peng Bo has been appointed as a non-executive Director and a member of the Strategic Committee of the Company with effect from 10 November 2023. Mr. Peng, born in 1968, was the chief marketing officer of the Company and the chairperson of Greater China Executive Committee of the Company. Mr. Peng joined the Group in 2001, and held various positions including market development manager, director of human resources and senior vice president of domestic sales and marketing department in the Group. Mr. Peng has over 24 years of experience in marketing and sales. From December 2021 to November 2023, Mr. Peng served as a non-executive director and chairperson of MicroPort NeuroTech Limited. Mr. Peng also has served as a director and chairperson of Shanghai MicroPort Endovascular MedTech (Group) Co. Ltd. since July 2018, which he has recently applied for resignation with effect from the closing of the forthcoming general meeting of EV MedTech. Mr. Peng received his bachelor's degree in Computer Science from Changchun University of Science and Technology in 1990 and his master's degree in Business Administration from Shanghai University of Finance & Economics in 2003. Reported Earnings • Sep 01
First half 2023 earnings released: US$0.089 loss per share (vs US$0.11 loss in 1H 2022) First half 2023 results: US$0.089 loss per share (improved from US$0.11 loss in 1H 2022). Revenue: US$482.6m (up 19% from 1H 2022). Net loss: US$162.6m (loss narrowed 18% from 1H 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings. Announcement • Aug 18
MicroPort Scientific Corporation to Report First Half, 2023 Results on Aug 30, 2023 MicroPort Scientific Corporation announced that they will report first half, 2023 results on Aug 30, 2023 Buying Opportunity • Jul 31
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 5.4%. The fair value is estimated to be €2.23, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.8% over the last 3 years. Meanwhile, the company became loss making. For the next 3 years, revenue is forecast to grow by 18% per annum. Earnings is also forecast to grow by 34% per annum over the same time period. Announcement • Jul 12
Microport Scientific Corporation Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2023 MicroPort Scientific Corporation provided consolidated earnings guidance for the six months ended June 30, 2023. For the six months ended 30 June 2023, the revenue of EV MedTech is expected to be between RMB 596.44 million and RMB 633.144 million, representing an increase of between approximately 30% and 38% as compared with the same period last year. The net profit attributable to the equity owners of EV MedTech is expected to be between RMB 268.7956 million and RMB 279.5474 million, representing an increase of between approximately 25% and 30% as compared with the same period last year. Announcement • Jun 21
MicroPort Scientific Corporation Announces Board Changes The Board of MicroPort Scientific Corporation announced that Dr. Yasuhisa Kurogi, a non-executive Director of the Company, who did not offer himself for re-election at the AGM in order to allow himself to devote more time to his other endeavours, has retired as a non-executive Director of the Company at the conclusion of the AGM. The Board announced that, with effect from the conclusion of the AGM, Mr. Hiroshi Shirafuji has been elected as a non-executive Director of the Company. His biographical details are set out below: Mr. Shirafuji, born in 1944, is the Honorary Chairman of the Company and a consultant of the Group. Mr. Shirafuji had served as a non-executive Director of the Company from November 2006 to June 2020. Mr. Shirafuji was executive director of Otsuka Medical Devices Co. from January 2017 to March 2017. From February 2011 to January 2017, he served as the President and Representative director of OMD. Prior to joining OMD in February 2011, he was an executive director responsible for pharmaceuticals marketing at Otsuka Pharmaceutical from 1997 to 1998. Mr. Shirafuji joined Otsuka Pharmaceutical in 1967. Mr. Shirafuji received his bachelor's degree in economics from Doshisha University in Kyoto in 1967. Recent Insider Transactions • Jun 06
Independent Non-Executive Director recently sold €247k worth of stock On the 30th of May, Jonathan H. Chou sold around 148k shares on-market at roughly €1.67 per share. This transaction amounted to 96% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €612k. Insiders have been net sellers, collectively disposing of €1.2m more than they bought in the last 12 months. Announcement • May 26
MicroPort Scientific Corporation, Annual General Meeting, Jun 19, 2023 MicroPort Scientific Corporation, Annual General Meeting, Jun 19, 2023, at 10:00 China Standard Time. Location: 1601 Zhangdong Road, Zhangjiang Hi-Tech Park, Shanghai 201203 Shangai China Agenda: To receive the audited consolidated financial statements of the Company and the reports of the directors and auditor for the year ended 31 December 2022; to re-elect the following directors of the Company; to elect Mr. Hiroshi Shirafuji as a non-executive Director of the Company; to authorize the board of directors of the Company to fix the respective Directors' remuneration; to re-appoint KPMG as auditor and to authorize the Board to fix its remuneration. Recent Insider Transactions • May 04
Independent Non-Executive Director recently sold €612k worth of stock On the 26th of April, Jonathan H. Chou sold around 300k shares on-market at roughly €2.04 per share. This transaction amounted to 66% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Breakeven Date Change • Apr 03
No longer forecast to breakeven The 10 analysts covering MicroPort Scientific no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$679.3m in 2025. New consensus forecast suggests the company will make a loss of US$365.5m in 2025. Reported Earnings • Mar 31
Full year 2022 earnings released: US$0.24 loss per share (vs US$0.15 loss in FY 2021) Full year 2022 results: US$0.24 loss per share (further deteriorated from US$0.15 loss in FY 2021). Revenue: US$840.8m (up 8.0% from FY 2021). Net loss: US$436.5m (loss widened 58% from FY 2021). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance. Announcement • Jan 14
Microport Scientific Corporation Announces That Hiroshi Shirafuji Has Accepted the Invitation to Act as the Honorary Chairman MicroPort Scientific Corporation announced that, Mr. Hiroshi Shirafuji ("Mr. Shirafuji") has accepted the invitation to act as the honorary chairman (the "Honorary Chairman") with effect from 13 January 2023. Mr. Shirafuji served as a non-executive director of the Company from November 2006 to June 2020. He witnessed the growth and development of the Company and made substantial contribution to the development of the Group. After retiring as a non-executive director of the Company, Mr. Shirafuji continued to pay attention to the strategy and business development of the Company and put forward constructive opinions and suggestions for the Company. Mr. Shirafuji possesses extensive experience in the medical device industry. The Board believes that the appointment of Mr. Shirafuji as the Honorary Chairman will enable the Company to continuously benefit from his experience and resources in the medical device industry. Board Change • Nov 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Chunyang Shao was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Sep 01
First half 2022 earnings released: US$0.11 loss per share (vs US$0.05 loss in 1H 2021) First half 2022 results: US$0.11 loss per share (down from US$0.05 loss in 1H 2021). Revenue: US$405.0m (up 5.3% from 1H 2021). Net loss: US$198.1m (loss widened 120% from 1H 2021). Over the next year, revenue is forecast to grow 32%, compared to a 8.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 114 percentage points per year, which is a significant difference in performance. Reported Earnings • Apr 29
Full year 2021 earnings released: US$0.15 loss per share (vs US$0.11 loss in FY 2020) Full year 2021 results: US$0.15 loss per share (down from US$0.11 loss in FY 2020). Revenue: US$778.6m (up 20% from FY 2020). Net loss: US$276.5m (loss widened 45% from FY 2020). Over the next year, revenue is forecast to grow 22%, compared to a 10% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 127 percentage points per year, which is a significant difference in performance. Board Change • Apr 27
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Chunyang Shao was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Apr 01
MicroPort Scientific Corporation, Annual General Meeting, Jun 23, 2022 MicroPort Scientific Corporation, Annual General Meeting, Jun 23, 2022. Reported Earnings • Apr 01
Full year 2021 earnings released: US$0.15 loss per share (vs US$0.11 loss in FY 2020) Full year 2021 results: US$0.15 loss per share (down from US$0.11 loss in FY 2020). Revenue: US$778.6m (up 20% from FY 2020). Net loss: US$276.5m (loss widened 45% from FY 2020). Over the next year, revenue is forecast to grow 22%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 137 percentage points per year, which is a significant difference in performance. Announcement • Apr 01
MicroPort Scientific Corporation Not to Recommend Final Dividend for the Year Ended 31 December 2021 The Directors of MicroPort Scientific Corporation do not recommend the payment of a final dividend for the year ended 31 December 2021 (2020: 4.3 HK cents (tax inclusive)). Announcement • Mar 07
MicroPort Scientific Corporation Provides Consolidated Earnings Guidance for the Full Year Ended December 31, 2021 MicroPort Scientific Corporation provided consolidated earnings guidance for the full year ended December 31, 2021. For the year, the Group achieved double digit year-on-year growth in sales revenue, which was principally attributable to rapid market penetration in the endovascular and peripheral vascular devices business, the cardiacrhythm management business, the neurovascular business and the heart valve business, contribution from new product launches, and the increase in elective surgeries from the easing of the COVID-19 pandemic. During the Reporting Period, the Group recorded loss attributable to equity shareholders of the Company of between approximately USD 275 million and USD 285 million, as compared with a loss of USD 191 million for the same period of last year. Reported Earnings • Sep 30
First half 2021 earnings released: US$0.05 loss per share (vs US$0.039 loss in 1H 2020) The company reported a soft first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: US$384.6m (up 25% from 1H 2020). Net loss: US$90.3m (loss widened 38% from 1H 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 173 percentage points per year, which is a significant difference in performance. Reported Earnings • Sep 01
First half 2021 earnings released: US$0.05 loss per share (vs US$0.039 loss in 1H 2020) The company reported a soft first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: US$384.6m (up 25% from 1H 2020). Net loss: US$90.3m (loss widened 38% from 1H 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 169 percentage points per year, which is a significant difference in performance. Board Change • Jul 29
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Chunyang Shao was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Upcoming Dividend • Jun 22
Upcoming dividend of HK$0.043 per share Eligible shareholders must have bought the stock before 28 June 2021. Payment date: 18 August 2021. Trailing yield: 0.1%. Lower than top quartile of German dividend payers (3.1%). Lower than average of industry peers (1.0%). Announcement • May 25
MicroPort Scientific Corporation Proposes Final Dividend for the Year Ended 31 December 2020 MicroPort Scientific Corporation proposed to declare and approve a final dividend of 4.3 Hong Kong cents (tax inclusive) per share in the capital of the
Company for the year ended 31 December 2020 by way of a scrip dividend scheme with an option to elect to receive wholly or partly by an allotment and issue of shares credited as fully paid in lieu of cash payment, at its AGM to be held on June 24, 2021. Reported Earnings • May 01
Full year 2020 earnings released: US$0.11 loss per share (vs US$0.029 profit in FY 2019) The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: US$648.7m (down 18% from FY 2019). Net loss: US$191.3m (down US$237.5m from profit in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 177 percentage points per year, which is a significant difference in performance. Reported Earnings • Mar 31
Full year 2020 earnings released: US$0.11 loss per share (vs US$0.029 profit in FY 2019) The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: US$648.7m (down 18% from FY 2019). Net loss: US$191.3m (down US$237.5m from profit in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 169 percentage points per year, which is a significant difference in performance. Is New 90 Day High Low • Jan 21
New 90-day high: €5.80 The company is up 86% from its price of €3.12 on 23 October 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.61 per share. Is New 90 Day High Low • Dec 29
New 90-day high: €4.38 The company is up 27% from its price of €3.44 on 30 September 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.60 per share. Is New 90 Day High Low • Dec 04
New 90-day high: €3.98 The company is up 2.0% from its price of €3.92 on 04 September 2020. The German market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.21 per share. Is New 90 Day High Low • Oct 28
New 90-day low: €3.04 The company is down 30% from its price of €4.32 on 29 July 2020. The German market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.20 per share. Is New 90 Day High Low • Sep 27
New 90-day low: €3.14 The company is down 1.0% from its price of €3.18 on 29 June 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Medical Equipment industry, which is also down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.14 per share. Reported Earnings • Sep 21
First half earnings released Over the last 12 months the company has reported total losses of US$84.8m, with earnings decreasing by US$150.3m from the prior year. Total revenue was US$707.8m over the last 12 months, down 5.9% from the prior year. Announcement • Aug 15
MicroPort Scientific Corporation to Report First Half, 2020 Results on Aug 27, 2020 MicroPort Scientific Corporation announced that they will report first half, 2020 results on Aug 27, 2020 
